Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Response rate as an endpoint in clinical trials.

Publication ,  Journal Article
George, SL
Published in: J Natl Cancer Inst
January 17, 2007

Duke Scholars

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

January 17, 2007

Volume

99

Issue

2

Start / End Page

98 / 99

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Osteosarcoma
  • Oncology & Carcinogenesis
  • Multicenter Studies as Topic
  • Humans
  • Europe
  • Drug Administration Schedule
  • Dose-Response Relationship, Drug
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, S. L. (2007). Response rate as an endpoint in clinical trials. J Natl Cancer Inst, 99(2), 98–99. https://doi.org/10.1093/jnci/djk024
George, Stephen L. “Response rate as an endpoint in clinical trials.J Natl Cancer Inst 99, no. 2 (January 17, 2007): 98–99. https://doi.org/10.1093/jnci/djk024.
George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst. 2007 Jan 17;99(2):98–9.
George, Stephen L. “Response rate as an endpoint in clinical trials.J Natl Cancer Inst, vol. 99, no. 2, Jan. 2007, pp. 98–99. Pubmed, doi:10.1093/jnci/djk024.
George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst. 2007 Jan 17;99(2):98–99.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

January 17, 2007

Volume

99

Issue

2

Start / End Page

98 / 99

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Randomized Controlled Trials as Topic
  • Osteosarcoma
  • Oncology & Carcinogenesis
  • Multicenter Studies as Topic
  • Humans
  • Europe
  • Drug Administration Schedule
  • Dose-Response Relationship, Drug
  • Disease-Free Survival